UVV vs MLTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
UVV · Universal Corp$39.41 ▼ 3.95%
MLTX · MoonLake Immunotherapeutics$11.53 ▲ 6.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- UVV -21.7%
- MLTX +6.6%
Head to head
| Metric | UVV | MLTX |
|---|---|---|
| Price | $39.41 | $11.53 |
| Change today | ▼ 3.95% | ▲ 6.76% |
| Market cap | $982.37M | $981.28M |
| Return, 3 months | -16.9% | -33.5% |
| Return, year to date | -21.7% | -12.5% |
| Return, 1 year | -22.5% | +8.5% |
| P/E (TTM) | – | – |
| P/B | 0.7 | 2.6 |
| P/E percentile vs own 5y | 96th | 90th |
| Dividend yield | 8.37% | – |
| Revenue growth (YoY, latest qtr) | -11.8% | – |
| Net profit growth (YoY) | -158.1% | -10.3% |
| Gross margin | 16.8% | – |
| Operating margin | 6.3% | – |
| Net margin | 0.7% | – |
| Return on equity | 1.3% | -67.4% |
| Analyst target vs. price | – | +177.5% |
| Analyst buy share | – | 88% |
| RSI (14) | 42 | 49 |
| 30-day volatility | 29.8% | 69.7% |
| Max drawdown, 1 year | -32.9% | -56.9% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- UVV is the largest of the group by market value.
- MLTX has returned the most over the past year.
- UVV has been the calmest stock over the last 30 days.